Astrazeneca (AZNCF) Payables (2016 - 2025)
Historic Payables for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to -$25.3 billion.
- Astrazeneca's Payables fell 1229.36% to -$25.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.3 billion, marking a year-over-year decrease of 1229.36%. This contributed to the annual value of -$25.3 billion for FY2025, which is 1229.36% down from last year.
- As of Q4 2025, Astrazeneca's Payables stood at -$25.3 billion, which was down 1229.36% from -$25.1 billion recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Payables registered a high of $22.2 billion during Q4 2023, and its lowest value of -$25.3 billion during Q4 2025.
- Moreover, its 5-year median value for Payables was -$19.6 billion (2023), whereas its average is -$14.7 billion.
- The largest annual percentage gain for Astrazeneca's Payables in the last 5 years was 25126.55% (2021), contrasted with its biggest fall of 671943.93% (2021).
- Astrazeneca's Payables (Quarter) stood at $18.6 billion in 2021, then increased by 1.13% to $18.9 billion in 2022, then increased by 17.57% to $22.2 billion in 2023, then tumbled by 201.59% to -$22.5 billion in 2024, then dropped by 12.29% to -$25.3 billion in 2025.
- Its Payables stands at -$25.3 billion for Q4 2025, versus -$25.1 billion for Q3 2025 and -$24.0 billion for Q2 2025.